Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report published on Tuesday. The firm issued a sell rating on the stock.

Oragenics Trading Up 29.6 %

NYSE OGEN traded up $0.32 during trading hours on Tuesday, hitting $1.40. The company had a trading volume of 1,739,745 shares, compared to its average volume of 185,378. The firm has a 50 day moving average of $1.25. The stock has a market cap of $6.27 million, a P/E ratio of -0.16 and a beta of 0.50. Oragenics has a 1-year low of $0.86 and a 1-year high of $7.74.

Oragenics (NYSE:OGEN) last announced its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is currently owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.